GSK3326595, also known as EPZ015938, is primarily used in the field of oncology research. It functions as a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), an enzyme implicated in various cancer types. By inhibiting PRMT5, this compound helps in studying the role of arginine methylation in tumor growth and survival. It is particularly valuable in preclinical studies for understanding its potential therapeutic effects in cancers such as lymphoma, leukemia, and solid tumors. Researchers utilize GSK3326595 to explore its impact on gene expression, cell proliferation, and apoptosis, providing insights into novel cancer treatment strategies. Its application extends to drug development, where it serves as a key tool for evaluating the efficacy of PRMT5 inhibition in targeted cancer therapies.